JP2021500405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500405A5 JP2021500405A5 JP2020542711A JP2020542711A JP2021500405A5 JP 2021500405 A5 JP2021500405 A5 JP 2021500405A5 JP 2020542711 A JP2020542711 A JP 2020542711A JP 2020542711 A JP2020542711 A JP 2020542711A JP 2021500405 A5 JP2021500405 A5 JP 2021500405A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- page
- patent document
- active drug
- prior
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 125000003636 chemical group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023007969A JP2023061949A (ja) | 2017-10-20 | 2023-01-23 | ダントロレンの生産物およびそれらの使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575124P | 2017-10-20 | 2017-10-20 | |
| US62/575,124 | 2017-10-20 | ||
| US201862674422P | 2018-05-21 | 2018-05-21 | |
| US62/674,422 | 2018-05-21 | ||
| PCT/US2018/056713 WO2019079721A1 (en) | 2017-10-20 | 2018-10-19 | DANTROLENE PRODRUGS AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023007969A Division JP2023061949A (ja) | 2017-10-20 | 2023-01-23 | ダントロレンの生産物およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500405A JP2021500405A (ja) | 2021-01-07 |
| JP2021500405A5 true JP2021500405A5 (https=) | 2021-09-09 |
| JP7252963B2 JP7252963B2 (ja) | 2023-04-05 |
Family
ID=64277793
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542711A Active JP7252963B2 (ja) | 2017-10-20 | 2018-10-19 | ダントロレンの生産物およびそれらの使用方法 |
| JP2023007969A Pending JP2023061949A (ja) | 2017-10-20 | 2023-01-23 | ダントロレンの生産物およびそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023007969A Pending JP2023061949A (ja) | 2017-10-20 | 2023-01-23 | ダントロレンの生産物およびそれらの使用方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11352347B2 (https=) |
| EP (2) | EP3697779B1 (https=) |
| JP (2) | JP7252963B2 (https=) |
| KR (1) | KR102652642B1 (https=) |
| CN (1) | CN111344286A (https=) |
| AU (2) | AU2018351494C1 (https=) |
| BR (1) | BR112020007858A2 (https=) |
| CA (1) | CA3079558A1 (https=) |
| CO (1) | CO2020006193A2 (https=) |
| ES (1) | ES3016835T3 (https=) |
| IL (1) | IL274045B2 (https=) |
| MA (1) | MA50403A (https=) |
| MX (2) | MX2020003400A (https=) |
| MY (1) | MY201417A (https=) |
| NZ (1) | NZ763377A (https=) |
| SG (1) | SG11202003452XA (https=) |
| UA (1) | UA127738C2 (https=) |
| WO (1) | WO2019079721A1 (https=) |
| ZA (1) | ZA202002779B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201417A (en) * | 2017-10-20 | 2024-02-21 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| US12246028B2 (en) * | 2018-11-27 | 2025-03-11 | Eagle Research Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| EP3771711A1 (en) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazole derivatives for controlling arthropods |
| AU2021254415A1 (en) | 2020-04-10 | 2022-10-20 | Eagle Pharmaceuticals, Inc. | Methods of treating Severe Acute Respiratory Syndrome |
| US12605364B2 (en) | 2020-04-10 | 2026-04-21 | Eagle Pharmaceuticals, Inc. | Methods of treating SARS-CoV-2 infections |
| WO2021207446A1 (en) | 2020-04-10 | 2021-10-14 | Eagle Pharmaceuticals, Inc. | Methods of treating viral infections |
| EP4132519A1 (en) | 2020-04-10 | 2023-02-15 | Eagle Pharmaceuticals, Inc. | Methods of treating coronavirus infections |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415821A (en) | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
| US4137402A (en) | 1978-03-30 | 1979-01-30 | Morton-Norwich Products, Inc. | Quaternary ammonium salts of dantrolene and clodanolene |
| US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TWI369982B (en) | 2007-01-11 | 2012-08-11 | Xenoport Inc | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| EP2583670A1 (en) * | 2007-10-09 | 2013-04-24 | US Worldmeds LLC | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| WO2009067175A2 (en) | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Oligomer-dantrolene conjugates and related compounds |
| US20090306163A1 (en) | 2008-06-10 | 2009-12-10 | Pamela Renee Lipkin | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| FR2944525B1 (fr) | 2009-04-17 | 2011-06-24 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| ES2592518T3 (es) | 2011-10-13 | 2016-11-30 | Merck Sharp & Dohme Corp. | Antagonistas del receptor de mineralocorticoides |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| EP2968229B1 (en) | 2013-03-15 | 2019-12-04 | Rosalind Franklin University of Medicine and Science | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| WO2014191837A2 (en) | 2013-05-06 | 2014-12-04 | University Health Network | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias |
| US9433608B2 (en) | 2013-05-08 | 2016-09-06 | Howard University | Compositions and method for treatment of ischemic neuronal reperfusion injury |
| HUP1300720A2 (hu) | 2013-12-12 | 2015-06-29 | Univ Szegedi | Gyógyászati készítmények sebgyógyulás elõsegítésére |
| JPWO2015182625A1 (ja) | 2014-05-26 | 2017-06-08 | 国立大学法人京都大学 | Ｒａｓ活性阻害薬及びその用途 |
| WO2016077706A1 (en) | 2014-11-13 | 2016-05-19 | Washington University | Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders |
| JP7409772B2 (ja) | 2015-10-20 | 2024-01-09 | スぺファーム アクチェンゲゼルシャフト | ダントロレンを含む水性組成物 |
| MY201417A (en) * | 2017-10-20 | 2024-02-21 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| SE542780C2 (en) | 2018-09-15 | 2020-07-07 | Coloreel Group AB | A system and method for in-line treatment of thread |
-
2018
- 2018-10-19 MY MYPI2020001973A patent/MY201417A/en unknown
- 2018-10-19 WO PCT/US2018/056713 patent/WO2019079721A1/en not_active Ceased
- 2018-10-19 MA MA050403A patent/MA50403A/fr unknown
- 2018-10-19 BR BR112020007858-1A patent/BR112020007858A2/pt active Search and Examination
- 2018-10-19 US US16/755,255 patent/US11352347B2/en active Active
- 2018-10-19 MX MX2020003400A patent/MX2020003400A/es unknown
- 2018-10-19 UA UAA202002979A patent/UA127738C2/uk unknown
- 2018-10-19 IL IL274045A patent/IL274045B2/en unknown
- 2018-10-19 ES ES18801102T patent/ES3016835T3/es active Active
- 2018-10-19 EP EP18801102.7A patent/EP3697779B1/en active Active
- 2018-10-19 SG SG11202003452XA patent/SG11202003452XA/en unknown
- 2018-10-19 JP JP2020542711A patent/JP7252963B2/ja active Active
- 2018-10-19 AU AU2018351494A patent/AU2018351494C1/en active Active
- 2018-10-19 CA CA3079558A patent/CA3079558A1/en active Pending
- 2018-10-19 EP EP25160825.3A patent/EP4574832A3/en active Pending
- 2018-10-19 NZ NZ763377A patent/NZ763377A/en unknown
- 2018-10-19 KR KR1020207013964A patent/KR102652642B1/ko active Active
- 2018-10-19 CN CN201880068207.9A patent/CN111344286A/zh active Pending
-
2020
- 2020-05-14 ZA ZA2020/02779A patent/ZA202002779B/en unknown
- 2020-05-20 CO CONC2020/0006193A patent/CO2020006193A2/es unknown
- 2020-07-13 MX MX2023010501A patent/MX2023010501A/es unknown
-
2022
- 2022-05-24 US US17/751,806 patent/US12269815B2/en active Active
-
2023
- 2023-01-23 JP JP2023007969A patent/JP2023061949A/ja active Pending
- 2023-12-08 AU AU2023278113A patent/AU2023278113B2/en active Active
-
2024
- 2024-10-17 US US18/918,855 patent/US20250145593A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500405A5 (https=) | ||
| HRP20150838T1 (hr) | Sastavi koji sadrže modulatore receptora sfingozin 1 fosfata (s1p) | |
| JP2021524958A5 (https=) | ||
| RU2008127490A (ru) | Композиции и капсулы с устойчивыми гидрофильными слоями | |
| RU2005101639A (ru) | Таблетка с замедленным высвобождением, содержащая ребоксетин | |
| JP2007507532A5 (https=) | ||
| NO20070719L (no) | Tablettformulering med forlenget frigivelse som inneholder pramipeksol eller et farmasoytisk akseptabelt salt derav, fremgangsmate for fremstilling av den og anvendelse derav | |
| CL2010001054A1 (es) | Mezcla pesticida que comprende la antranilamida 3- bromo-n- [4-cioan-2-metil -6- [(metilamino)- carbonil] fenil] -1-(3 cloro-2-piridinil)-1h- pirazol -5- carboxamida y un segundo agente activo selecto entre inhibidores de la colinesterasa; composiciones y metodo que emplean dicha mezcla para combatir plagas de invertebrados (divisional de 1856-2005). | |
| PE20100432A1 (es) | Metilamida del acido 4{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi)-piridin-2-carboxilico y sus sales farmaceuticamente aceptables | |
| ME01458B (me) | Kruta dozna forma koja sadrži inhibitor protonske pumpe i njena suspenzija | |
| JP2005533780A5 (https=) | ||
| BR9910583A (pt) | Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios | |
| NO343603B1 (no) | Forbindelse for anvendelse for behandling av søvnighet på dagtid assosiert med Parkinsons sykdom eller obstruktiv søvnapné, samt kombinasjon omfattende forbindelsen med et anti-parkinson medikament. | |
| PE20081751A1 (es) | Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor | |
| JP2022521336A5 (https=) | ||
| Markham | Solriamfetol: first global approval | |
| CN114269751A (zh) | 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途 | |
| JP2015518007A5 (https=) | ||
| Notario-Pérez et al. | Mucoadhesive vaginal discs based on cyclodextrin and surfactants for the controlled release of antiretroviral drugs to prevent the sexual transmission of HIV | |
| WO2009121155A3 (en) | Flavone containing compositions for treating mao associated disorders | |
| Badavath et al. | Design, in-silico docking and predictive ADME properties of novel pyrazoline derivatives with selective human MAO inhibitory activity | |
| Badavath et al. | MAO Inhibitory Activity of 4, 5-Dihydro-1 HPyrazole Derivatives: A Platform To Design Novel Antidepressants | |
| JP2005527477A5 (https=) | ||
| MA38697A1 (fr) | 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7 | |
| FI3952872T3 (fi) | Karbamoyylisykloheksaanijohdannaisia autismikirjon häiriön hoitamiseksi |